Shots:
- Kelun-Biotech has reported P-III (OptiTROP-Lung06) trial data assessing sacituzumab tirumotecan (sac-TMT/SKB264/MK-2870) + Keytruda vs CT + Keytruda as the 1L treatment for PD-L1-negative locally advanced or metastatic non-squamous NSCLC (TPS <1%)
- IDMC has concluded that the trial met its 1EP of improved PFS at interim analysis vs Keytruda + pemetrexed & Pt-based CT, plus a favorable trend in OS (2EP) was observed; data will be shared with NMPA’s CDE
- Sac-TMT, a human TROP2 ADC, is being evaluated in ten registrational trials in lung cancer, incl. 5 Chinese studies & 5 global P-III trials
Ref: PRnewswire | Image: Kelun-Biotech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
